
Alivus Life Sciences Share Price Target 2025 to 2030: Hello Friends, today we are going to give you complete information about Alivus Life Sciences Share Price. If you want to know what is the future of this Share Price and what is its target? So we will give you complete information about this Share in detail.
Alivus Life Sciences Share Price Target
If we talk about Alivus Life Sciences Share Price Target, then its share is going to increase in the coming 10 years. Talking about its performance, this stock has performed well in the last few months and has given money to all the investors. Investors of this Share are increasing very fast and all the investors are also investing funds. If you are a long-term investor then this share will give you good returns.
Alivus Life Sciences Company Details
Glenmark Life Sciences Limited, a company based in India, focuses mainly on developing, producing, and promoting active pharmaceutical ingredients (API). The Company offers a range of products across multiple therapeutic areas, including cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management.
Fundamental Details
- P/E Ratio (TTM): 26.29
- EPS (TTM): 39.60
- Dividend Yield: 0.48%
- Market Cap: ₹12,768Cr
Financial Details
2020 | 2021 | 2022 | 2023 | 2024 | |
Revenue | Rs. 1,549 Cr | Rs. 1,886 Cr | Rs. 2,138 Cr | Rs. 2,190 Cr | Rs. 2,295 Cr |
Profit | Rs. 313 Cr | Rs. 352 Cr | Rs. 419 Cr | Rs. 467 Cr | Rs. 471 Cr |
Net Worth | Rs. 402 Cr | Rs. 753 Cr | Rs. 2,054 Cr | Rs. 2,138 Cr | Rs. 2,332 Cr |
Alivus Life Sciences Share Price Target 2025 to 2030
Alivus Life Sciences Share Price Target 2025 ₹1128.69, 2026 ₹1297.63, 2027 ₹1421.91, 2028 ₹1587.56, 2029 ₹1751.37, 2030 ₹1923.39.
Alivus Life Sciences Share Price Target | Price |
Alivus Life Sciences Share Price Target 2025 | ₹1128.69 |
Alivus Life Sciences Share Price Target 2026 | ₹1297.63 |
Alivus Life Sciences Share Price Target 2027 | ₹1421.91 |
Alivus Life Sciences Share Price Target 2028 | ₹1587.56 |
Alivus Life Sciences Share Price Target 2029 | ₹1751.37 |
Alivus Life Sciences Share Price Target 2030 | ₹1923.39 |
Alivus Life Sciences Share Price Target 2025
If we predict Alivus Life Sciences Share for 2025, then looking at the growth of this share, the expectation is that this share will increase the money of all the investors and will give profit to all the investors. Looking at the market growth of this share, it is expected that this share will grow from Upto ₹ 1128.69 by the end of 2025. Alivus Life Sciences Share Price Target for 2025 is ₹1128.69.
Alivus Life Sciences Share Price Target 2025 | ₹1128.69 |
Alivus Life Sciences Share Price Target 2030
Talking about Alivus Life Sciences Share, this share is on a bullish trend every year and the year ending of this share is with profit only. If we talk about 2030, then it is expected that this share will close upto ₹1923.39 this year. Looking at the bullish trend of this stock, it is expected that this year too it will add profit by making the money of all its investors profitable. Alivus Life Sciences Share Price Target for 2030 is ₹1923.39.
Alivus Life Sciences Share Price Target 2030 | ₹1923.39 |
Also Read: Anand Rathi Wealth Share Price Target
Also Read: Aarti Industries Share Price Target
Also Read: Alembic Pharmaceuticals Share Price Target
Also Read: Anant Raj Share Price Target
Also Read: Asahi India Glass Share Price Target
Disclaimer: This article is for informational purposes only and should not be considered investment advice. The price targets or predictions provided are generated by a custom algorithm using deep learning, which may change due to market fluctuations, volume shifts, and market cycles. It is strongly recommended not to base investments solely on the target price mentioned. |

I’m Rakesh Goswami, a Computer Science engineer with over 5 years of experience in blogging. I specialize in stock market research and share price target analysis. Through this website, I aim to provide clear and reliable insights to help readers make informed investment decisions.